Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility |
| |
Authors: | Shree Divyya Shaik Mohammad Naushad Anthony Addlagatta PVLN Murthy Ch Ram Reddy Raghunadha Rao Digumarti Suryanarayana Raju Gottumukkala Ajit Kumar S Rammurti Vijay Kumar Kutala |
| |
Institution: | 1. Department of Clinical Pharmacology & Therapeutics, Nizam''s Institute of Medical Sciences, Hyderabad-500082, India;2. Center for Chemical Biology, Indian Institute of Chemical Technology, Hyderabad-500007, India;3. Department of Urology, Nizam''s Institute of Medical Sciences, Hyderabad-500082, India;4. Department of Medical Oncology, Nizam''s Institute of Medical Sciences, Hyderabad-500082, India;5. Department of Surgical Oncology, Nizam''s Institute of Medical Sciences, Hyderabad-500082, India;6. Department of Gastroenterology, Nizam''s Institute of Medical Sciences, Hyderabad-500082, India;g Department of Radiology and Imageology, Nizam''s Institute of Medical Sciences, Hyderabad-500082, India |
| |
Abstract: | Glutamate carboxypeptidase II (GCPII) is predominantly expressed in brain, intestinal mucosa and prostate cancer in the form of three splice variants i.e. N-acetylated-α-linked acidic dipeptidase (NAALADase), folyl poly-γ-glutamate carboxypeptidase (FGCP) and prostate specific membrane antigen (PSMA) respectively. Its inhibition was found to confer protection against certain neurological disorders and cancer. Despite the pivotal role of this enzyme, the most common polymorphism i.e. H475Y has not been explored comprehensively in all its splice variants. In this study, we have determined the role of this variant in different disease conditions such as breast and prostate cancers, autism, coronary artery disease (CAD) and miscarriages (N = 1561). Genotyping was done by PCR-RFLP and dideoxy sequencing. Plasma folate levels were estimated by Axysm folate kit. GCPII expression was studied by semi-quantitative RT-PCR. In silico model was developed using PYMOL. We observed the protective role of H475Y variant in cancers breast cancer; OR (95% CI): 0.81 (0.55–1.19), prostate cancer: OR (95% CI): 0.00 (0.00–0.66)], and in autism (OR (95% CI): 0.47 (0.21–1.03), whereas inflated risk was observed in CAD (OR (95% CI): 1.69 (1.20–2.37) and miscarriages Maternal OR (95% CI): 3.26 (2.11–5.04); Paternal OR(95% CI): 1.99 (1.23–3.21)]. Further, this variant was found to impair the intestinal folate absorption in subjects with dietary folate intake in the lowest tertile (CC vs. CT in lowest tertile; 7.56 ± 0.85 ng/ml vs. 2.73 ± 045 ng/ml, p = 0.005). In silico model of GCPII showed steric hindrance with H475Y resulting in stereochemical alteration of catalytic site, thus interfering with ligand binding. Statistically significant association was not observed between dietary folate levels and GCPII expression. However, a positive correlation was seen between plasma folate levels and GCPII expression (r = 0.70, p < 0.05). To conclude, our data suggests that GCPII H475Y variant shows inverse association with autism and cancer while showing positive association with CAD and miscarriages. |
| |
Keywords: | ABC Autism Behaviour Checklist DQ Development Quotient DSM-IV Diagnostic and Statistical Manual of Mental Disorders FGCP folyl poly-γ-glutamate carboxypeptidase GCP II Glutamate carboxypeptidase II 5-HT2A Serotonin receptor 2A NAALADase N-acetylated-α-linked acidic dipeptidase NAAG N-acetyl aspartyl glutamate NTDs Neural tube defects NMDA N-methyl-d-aspartate ODS Octa decyl silane PSMA Prostate specific membrane antigen TGF Transforming Growth Factor |
本文献已被 ScienceDirect 等数据库收录! |
|